Elizabeth-Barbara Tatsi

Dr. Elizabeth-Barbara Tatsi

National and Kapodistrian University of Athens School of Health Sciences, Department of Medicine, Athens, Greece
+1
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2021 in Epidemiology and Infection
Verified
Journal Article
Open access
PDF file
Elizabeth-Barbara TatsiElizabeth-Barbara Tatsi
Elizabeth-Barbara Tatsi
Filippos FilippatosFilippos Filippatos
Filippos Filippatos
Athanasios MichosAthanasios Michos
Athanasios Michos
The SARS-CoV-2 virus is rapidly evolving via mutagenesis, lengthening the pandemic, and threatening the public health. Until August 2021, 12 variants of SARS-CoV-2 named as variants of concern (VOC; Alpha to Delta) or variants of interest (VOI; Epsilon to Mu), with significant impact on transmissibility, morbidity, possible reinfection and mortality, have been identified. The VOC Delta (B.1.617.2) of Indian origin is now the dominant and the most contagious variant worldwide as it provokes a strong binding to the human ACE2 receptor, increases transmissibility and manifests considerable immune escape strategies after natural infection or vaccination. Although the development and administration of SARS-CoV-2 vaccines, based on different technologies (mRNA, adenovirus carrier, recombinant protein, etc.), are very promising for the control of the pandemic, their effectiveness and neutralizing activity against VOCs varies significantly. In this review, we describe the most significant circulating variants of SARS-CoV-2, and the known effectiveness of currently available vaccines against them.

4 January 2024 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
PBPaul Bastard
Paul Bastard
AGAdrian Gervais
Adrian Gervais
MTMaki Taniguchi
Maki Taniguchi
LSLiisa Saare
Liisa Saare
KSKarita Särekannu
Karita Särekannu
JCJean-Laurent Casanova
Jean-Laurent Casanova
We found that 19 (10.4%) of 183 unvaccinated children hospitalized for COVID-19 pneumonia had autoantibodies (auto-Abs) neutralizing type I IFNs (IFN-α2 in 10 patients: IFN-α2 only in three, IFN-α2 plus IFN-ω in five, and IFN-α2, IFN-ω plus IFN-β in two; IFN-ω only in nine patients). Seven children (3.8%) had Abs neutralizing at least 10 ng/ml of one IFN, whereas the other 12 (6.6%) had Abs neutralizing only 100 pg/ml. The auto-Abs neutralized both unglycosylated and glycosylated IFNs. We also detected auto-Abs neutralizing 100 pg/ml IFN-α2 in 4 of 2,267 uninfected children (0.2%) and auto-Abs neutralizing IFN-ω in 45 children (2%). The odds ratios (ORs) for life-threatening COVID-19 pneumonia were, therefore, higher for auto-Abs neutralizing IFN-α2 only (OR [95% CI] = 67.6 [5.7–9,196.6]) than for auto-Abs neutralizing IFN-ω only (OR [95% CI] = 2.6 [1.2–5.3]). ORs were also higher for auto-Abs neutralizing high concentrations (OR [95% CI] = 12.9 [4.6–35.9]) than for those neutralizing low concentrations (OR [95% CI] = 5.5 [3.1–9.6]) of IFN-ω and/or IFN-α2.

1 September 2021 in Vaccine
Verified
Journal Article
Closed access
Athanasios MichosAthanasios Michos
Athanasios Michos
Elizabeth-Barbara TatsiElizabeth-Barbara Tatsi
Elizabeth-Barbara Tatsi
FFFilippos Filippatos
Filippos Filippatos
CDCharilaos Dellis
Charilaos Dellis
DKDimitra Koukou
Dimitra Koukou
VSVasiliki Syriopoulou
Vasiliki Syriopoulou

11 October 2019 in Pediatric Diabetes
Verified
Journal Article
Closed access
PDF file
Elizabeth-Barbara TatsiElizabeth-Barbara Tatsi
Elizabeth-Barbara Tatsi
CKChristina Kanaka‐Gantenbein
Christina Kanaka‐Gantenbein
ASAndreas Scorilas
Andreas Scorilas
GCGeorge P. Chrousos
George P. Chrousos
ASAmalia Sertedaki
Amalia Sertedaki

6 July 2021 in Biosensors
Verified
Journal Article
Open access
PDF file
Sofia MavrikouSofia Mavrikou
Sofia Mavrikou
VTVasileios Tsekouras
Vasileios Tsekouras
KHKYRIAKI HATZIAGAPIOU
KYRIAKI HATZIAGAPIOU
FPFoteini Paradeisi
Foteini Paradeisi
Petros BakakosPetros Bakakos
Petros Bakakos
Spyridon KintziosSpyridon Kintzios
Spyridon Kintzios
The availability of antigen tests for SARS-CoV-2 represents a major step for the mass surveillance of the incidence of infection, especially regarding COVID-19 asymptomatic and/or early-stage patients. Recently, we reported the development of a Bioelectric Recognition Assay-based biosensor able to detect the SARS-CoV-2 S1 spike protein expressed on the surface of the virus in just three minutes, with high sensitivity and selectivity. The working principle was established by measuring the change of the electric potential of membrane-engineered mammalian cells bearing the human chimeric spike S1 antibody after attachment of the respective viral protein. In the present study, we applied the novel biosensor to patient-derived nasopharyngeal samples in a clinical set-up, with absolutely no sample pretreatment. More importantly, membrane-engineered cells were pre-immobilized in a proprietary biomatrix, thus enabling their long-term preservation prior to use as well as significantly increasing their ease-of-handle as test consumables. The plug-and-apply novel biosensor was able to detect the virus in positive samples with a 92.8% success rate compared to RT-PCR. No false negative results were recorded. These findings demonstrate the potential applicability of the biosensor for the early, routine mass screening of SARS-CoV-2 on a scale not yet realized.

17 August 2021 in Pediatric Investigation
Verified
Journal Article
Open access
PDF file
FFFilippos Filippatos
Filippos Filippatos
Elizabeth-Barbara TatsiElizabeth-Barbara Tatsi
Elizabeth-Barbara Tatsi
Athanasios MichosAthanasios Michos
Athanasios Michos
Host immune responses to severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), especially in children, are still under investigation. Children with coronavirus disease 2019 (COVID‐19) constitute a significant study group of immune responses as they rarely present with severe clinical manifestations, require hospitalization, or develop complications such as multisystem inflammatory syndrome in children (MIS‐C) associated with SARS‐CoV‐2 infection. The deciphering of children’s immune responses during COVID‐19 infection will provide information about the protective mechanisms, while new potential targets for future therapies are likely to be revealed. Despite the limited immunological studies in children with COVID‐19, this review compares data between adults and children in terms of innate and adaptive immunity to SARS‐CoV‐2, discusses the possible reasons why children are mostly asymptomatic, and highlights unanswered or unclear immunological issues. Current evidence suggests that the activity of innate immunity seems to be crucial to the early phases of SARS‐CoV‐2 infection and adaptive memory immunity is vital to prevent reinfection.